Interval debulking surgery for advanced epithelial ovarian cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gynecologic Oncology

Background:

• Advanced epithelial ovarian cancer (stages III-IV) often requires treatment when primary debulking surgery is not feasible.
• Interval debulking surgery (IDS) is an option following neoadjuvant chemotherapy for these patients.

Purpose of the Study:

• To evaluate the effectiveness and complications of interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer.
• To compare survival outcomes between IDS and conventional treatment (primary surgery followed by adjuvant chemotherapy).

Main Methods:

• A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted.
• Searches included Cochrane Gynaecological Cancer Group Register, CENTRAL, MEDLINE, and EMBASE up to June 2012.
• Overall survival (OS) and progression-free survival (PFS) were analyzed using random-effects models.

Main Results:

• Three RCTs involving 853 women were included. No significant difference in OS or PFS was found between IDS and chemotherapy alone.
• Subgroup analysis indicated a survival benefit for IDS in patients whose primary surgery was less extensive or not performed by gynecologic oncologists.
• Chemotherapy toxicity rates were similar; data on other adverse events and quality of life were limited.

Conclusions:

• Current evidence does not conclusively support or refute the use of IDS to improve survival in advanced ovarian cancer compared to conventional treatment.
• IDS may offer benefits in specific patient subgroups with less optimal primary surgical outcomes.
• Further research is needed on quality of life and adverse events associated with IDS.